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           In the last 20 yr, many human melanoma anti-
gens recognized by T cells have been identifi  ed 
using various methods such as cDNA cloning, 
MHC-bound peptide purifi  cation, or T cell in-
duction against candidate peptides or proteins. 
These antigens have been classifi  ed into several 
groups: melanocytic diff  erentiation antigens 
(such as Melan-A/MART-1) (  1  ); cancer-germ-
line antigens, shared by several tumors and male 
germline cells (such as MAGE antigens) (  2, 3  ); 
mutated antigens generated by genetic altera-
tions (such as CDK4) (  4  ); antigens overexpressed 
in various tumor types (such as PRAME) (  5  ); 
and antigens aberrantly expressed in tumors (such 
as NA17-A and NA88-A) (  6, 7  ). However, de-
spite their high number, the immunogenicity 
of these antigens has not been elucidated yet, 
with the exception of Melan-A/MART-1. In-
deed, the immunogenicity of the Melan-A an-
tigen in melanoma has been strongly suggested 
by the analysis of several active (  8, 9  ) and pas-
sive (  10  –  15  ) immunotherapy protocols targeting 
this antigen. The identifi  cation of such tumor 
antigens with a documented immunogenic po-
tential remains a major issue to address for fu-
ture immunotherapy protocols. 
  To this aim, we studied tumor-infi  ltrating 
lymphocyte (TIL) populations that had been 
infused to melanoma patients in an adjuvant 
setting between 1994 and 2006, and who are 
still relapse free (  14, 16  ). We previously showed 
that the prevention of relapse was correlated 
with the infusion of tumor-specifi  c T cells (  17  ), 
and specifi  cally for HLA-A*0201 patients, with 
the infusion of Melan-A  –  specific TILs (  14  ). 
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  A cytotoxic T lymphocyte (CTL) clone was derived from a tumor-infi  ltrating lymphocyte 
(TIL) population infused to a melanoma patient who remained relapse free for 10 yr after 
this adoptive transfer. This clone recognized all melanoma cell lines tested and, to a lower 
extent, melanocytes, in the context of human histocompatibility leukocyte antigen A2 
(HLA-A2), but it did not recognize other tumor cell types. The gene coding for the antigen 
recognized by this clone was identifi  ed by the screening of a melanoma complementary 
DNA expression library. This antigen is overexpressed in melanomas, compared with other 
cancer cell lines and healthy tissues, and was thus called   melanoma-overexpressed antigen   
(  meloe  ). Remarkably, the structure of   meloe   was unusual, with multiple short open reading 
frames (ORFs). The peptide recognized by the CTL clone was encoded by one of these ORFs, 
called MELOE-1. Using a specifi  c HLA-A2/peptide tetramer, we showed a correlation 
between the infusion of TILs containing MELOE-1  –  specifi  c T cells and relapse prevention 
in HLA-A2 patients. Indeed, 5 out of 9 patients who did not relapse were infused with TILs 
that contained MELOE-1  –  specifi  c T cells, whereas 0 out of the 21 patients who relapsed 
was infused with such TIL-containing lymphocytes. Overall, our results suggest that this 
new antigen is involved in immunosurveillance and, thus, represents an attractive target 
for immunotherapy protocols of melanoma. 
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it after a cloning step.   This insert, namely   meloe  , spanning 2,128 
bp, was sequenced and was found to contain a poly(A) tail and 
to be similar to the clone BC008026 isolated by the National 
Institutes of Health (NIH) Mammalian Gene Collection con-
sortium (  21  ). After expression vector cloning, cotransfection of 
BC008026 cDNA with HLA A*0201 into COS-7 cells also 
induced the recognition by the M170.48 T cell clone (  Fig. 2 A  ), 
although these two sequences diff  ered by four single nucleo-
tide polymorphisms (SNPs;   Fig. 2 B  ). To control the impact of 
these SNPs on the recognition of the M170.48 T cell clone, 
we sequenced the cDNA isolated from recognized (M134 and 
M117) and nonrecognized cell lines (A498 and SW480), and 
showed that this polymorphism did not aff  ect tumor cell line 
recognition. The   meloe   sequence analysis showed a perfect co-
linearity with the genomic DNA, obtained by comparison with 
the sequence of the human genome released by Celera (  22  ), 
Nonetheless, in several TIL populations infused to relapse-
free patients, a signifi  cant fraction of tumor-specifi  c TILs 
remains of unknown specifi  city. To fully characterize these 
tumor-specifi  c TILs and to look for new tumor antigens in-
volved in relapse prevention, we used a TIL population in-
fused to patient M170 in 1998, who is still relapse free today 
(  18  ). This HLA-A2 TIL population contained a signifi  cant 
fraction of melanoma-reactive TILs, among which Melan-A/
A2  –  specifi   c lymphocytes and lymphocytes of unknown 
specifi  city were present. In this study, we show that this TIL 
population contained tumor-reactive lymphocytes specifi  c for 
a new tumor antigen overexpressed in melanomas, mela-
noma-overexpressed antigen 1 (MELOE-1), and recognized 
by autologous TILs in the HLA-A2 context. Our study clearly 
shows a correlation between the infusion of T cells reactive 
against this new tumor epitope and relapse prevention of 
TIL-treated patients. Thus, this new antigen represents an at-
tractive target for immunotherapy protocols of melanoma. 
    RESULTS   
  T cell clone selection and characterization 
  The M170 TIL population contained 16% of melanoma-
reactive lymphocytes, among which 5% were specifi  c for the 
Melan-A/A2 epitope and 11% were of unknown specifi  city 
(  Fig. 1 A  ).   This TIL population was then tested for recogni-
tion of a large panel of known antigens (  Table I  ) transfected 
into COS cells with the class I HLA molecules of patient 
M170 (  14, 19  ), and no response aside from the Melan-A/A2 
response could be detected (unpublished data), suggesting that 
this population contained lymphocytes specifi  c for new tu-
mor antigens.   To characterize them, we derived tumor-reac-
tive CD8  +   T cell clones by limiting dilution. Eight of these 
CTL clones showed reactivity patterns consistent with the 
recognition of new antigens, and one of them, hereafter re-
ferred to as M170.48, was further characterized to determine 
the HLA context restricting its recognition. As illustrated by 
  Fig. 1 B  , the recognition of the autologous melanoma cell line 
occurs in the HLA-A2 context. To establish the distribution 
of the target antigen, we tested M170.48 reactivity toward 
various HLA-A2 tumor cell lines, including melanomas, ovar-
ian carcinomas, lung carcinomas, breast carcinomas, renal car-
cinomas, and colon carcinomas, using a TNF release assay. As 
shown in   Fig. 1 C  , this T cell clone recognized all of the 
HLA-A2 melanoma cell lines tested but none of the other 
HLA-A2 tumor cell types. In addition, the M170.48 T cell 
clone weakly recognized HLA-A2 melanocytes (  Fig. 1 D  ). 
However, this reactivity was much lower than that seen with 
a Melan-A/A2  –  specifi  c T cell clone (  Fig. 1 D  , hatched bars). 
  Identifi  cation of the cDNA coding for the antigen 
  We screened a cDNA library derived from the M134 mela-
noma cell line (  20  ) in COS-7 cells cotransfected with pHLA-
A*0201 to characterize the antigen recognized by the M170.48 
T cell clone. Among 800 pools of 100 pcDNA tested, one 
plasmid pool proved positive in this test, and the individual 
plasmid coding for the recognized antigen was recovered from 
    Figure 1.         T cell clone selection and characterization.   (A)  Percentage 
of TNF-producing T cells and of HLA-A2/Melan-A  A27L   tetramer – positive  T 
cells in the M170 TIL population in response to the autologous melanoma 
cell line. 10  5   TILs and 2   ×   10  5   melanoma cells were incubated for 5 h in the 
presence of Brefeldin A, stained with HLA-A2/Melan-A  A27L   tetramer,  fi  xed, 
and stained with anti-TNF antibody in a permeabilization buffer. 10  4   T  cells 
were then analyzed by fl  ow cytometry. (B) TNF secretion by the M170.48 T 
cell clone in response to the autologous melanoma cell line. 10  4   CTLs  were 
added to 3   ×   10  4   M170 melanoma cells in the presence of blocking anti-
bodies directed against class I, A2, and B/C HLA, diluted to 1:50 (shaded 
bars), 1:500 (hatched bars), and 1:5,000 (open bars). CTL clone reactivity was 
assessed by a TNF release assay. (C) TNF response of the M170.48 CTL clone 
to HLA-A*0201 tumor cell lines. The M6 cell line (HLA-A2 negative) was used 
as a negative control. (D) IFN-     response of the M170.48 CTL clone (shaded 
bars) and of a Melan-A/A2  –  specifi  c CTL clone (hatched bars) to HLA-A*0201 
melanocytes. The M170 cell line was added as a positive control.    JEM VOL. 205, October 27, 2008 
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are illustrated in   Fig. 3 A  .   The putative ORF described by 
the NIH Mammalian Gene Collection consortium was lo-
cated between 486 and 689 bp (  21  ). We tested this ORF and 
three additional ORFs (  Fig. 3 A  , black boxes) for recognition 
by M170.48, after transfection into COS-7 cells, with the 
HLA-A*0201 cDNA (  Fig. 3 B  ). The ORFs tested (  Table II  ) 
were chosen on the basis of preliminary results obtained on 
PCR fragments of   meloe   (unpublished data).   
  The ORF 1,230  –  1,370 bp encodes the protein bearing 
the peptide recognized by the specifi  c T cell clone. This 
ORF encodes a 46  –  amino acid protein that contains two 
peptides (positions 16  –  24 and 36  –  44 on the protein se-
quence) able to bind to the HLA A*0201, with a high stabil-
ity as predicted by BioInformatics and Molecular Analysis 
Section analysis (http://www-bimas.cit.nih.gov;   Fig. 3 C  ). 
These two nonapeptides were tested for their recognition 
by the M170.48 T cell clone after loading onto T2 cells. 
Only the sequence 36  –  44 (TLNDECWPA) was recognized 
(  Fig. 3 D   and not depicted). We then tested the recognition 
of two additional peptides derived from this nonapeptide. 
We observed that addition of the serine at the C terminus 
(position 45) dramatically decreased the response of our 
CTL clone (  Fig. 3 D  , closed circles) and that deletion of the 
alanine at the C-terminal end (position 44) abrogated the 
CTL clone response (  Fig. 3 D  , open circles). In conclusion, 
the optimal peptide appeared to be the nonapeptide 36  –  44 
(TLNDECWPA), with a half-maximal lysis of 10      8   M (  Fig. 
3 D  , closed squares). 
which indicated absence of splicing. Finally, this sequence was 
found to be located in the third intron of the histone deacetylase 
(HDAC) 4 gene (Ensembl accession no. ENSG00000068024), 
on chromosome 2, in anti-sense orientation compared with 
the sequence of the HDAC-4 gene. 
  Identifi  cation of the peptide recognized by the M170.48 
T cell clone 
  The   meloe   cDNA does not contain a long open reading frame 
(ORF) but multiple short ORFs. ORFs longer than 90 bp 
    Table I.        Antigen-coding cDNAs transfected into COS cells 
No. Name
Shared tumor specifi  c 1 MAGE-1
2 MAGE-2
3 MAGE-3
4 MAGE-4
5 MAGE-6
6 MAGE-12
7 GAGE-1
8 GAGE-2
9 GAGE-3
10 GAGE-4
11 GAGE-5
12 GAGE-6
13 Lage-1a
14 Lage-1b
15 Lage-2
16 NA88-A
17 NA17-A
18 NA-134-A
19 BAGE
20 MAGE-C2
Differentiation 21 Melan-A
22 gp100
23 Tyrosinase
24 MC1R
25 TRP-2
26 gp75
27 NY-Mel-1
Mutated/other 28 Ras wild type
29 Mutated Ras
30 HSP70
31 h-TERT
32 survivin
Overexpressed 33 RAGE-1
34 RAGE-2
35 RAGE-3
36 RAGE-4
37 P53
38 PRAME
39 Her2-neu
40 EphA2
41 STEAP
    Figure 2.         Characterization of the cDNA coding for the recognized 
antigen.   (A) M170.48 TNF responses to COS-7 cells (E/T ratio = 1:3) trans-
fected with the indicated plasmids. The T cell clone was added 2 d after 
the transfection, and the CTL clone reactivity was assessed by a TNF re-
lease assay. (B) Comparison of the nucleotide sequences of   meloe   and 
BC008026 cDNAs and the localization of this sequence on the HDAC-4 
gene. The indicated nucleotides correspond to SNPs between the   meloe  
sequence isolated from M134 and A498 tumor cell lines and the   meloe  
sequence isolated from the M117 and SW480 cell lines, and the BC008026 
cDNA sequence.     2676 MELOE-1: AN ANTIGEN INVOLVED IN IMMUNOSURVEILLANCE   | Godet et al. 
transfection of   meloe   or   meloe-1   cDNA in HLA-A2 nonrecog-
nized tumor cell lines induced their recognition by the 
M170.48 T cell clone (  Fig. 4 B  ), showing that the absence of 
recognition of these tumor cell lines was caused by the under-
expression of   meloe   cDNA. Finally, to address the question of 
the expression of this antigen in healthy tissues, we performed 
qPCR on a panel of 16 tissues. It appears that the expression 
of   meloe   in healthy tissues was always lower than in melano-
cytes. The highest   meloe   expression was found in the whole 
and fetal brain but remained, respectively, 1.5- and 1.8-fold 
below its expression in melanocytes (  Fig. 4 C  ). Overall, these 
results suggest that this antigen could be safely targeted in 
immunotherapy protocols in melanoma, provided that its 
immunogenicity could be documented. 
  Presence of MELOE-1  –  specifi  c lymphocytes in TIL 
populations infused to relapse-free patients 
  To address the question of the immunogenicity of this new 
epitope, we used a specifi  c HLA-A2/peptide tetramer to look 
for the presence of specifi  c lymphocytes among 30 HLA-A2 
TIL populations derived from melanoma-invaded lymph 
nodes. All of those TIL populations had been infused to mel-
anoma patients in an adjuvant setting between the years 1998 
and 2002. After this treatment, 21 of these patients relapsed 
and 9 remained relapse free. Using a specifi  c HLA/peptide 
tetramer, we detected the presence of MELOE-1/A2  –  specifi  c 
T cells in fi  ve out of nine TIL populations that had been infused 
to relapse-free patients, with frequencies ranging from 0.07 to 
3.8% among CD8  +   TILs (  Fig. 5 A  , top).   In contrast, we did 
not observe the presence of such T cells among the TILs in-
fused to the 21 HLA-A2 patients who relapsed. An example of 
5 out of these 21 negative TIL populations is shown in   Fig. 5 A   
(bottom). These results document the existence of a correla-
tion between the presence of MELOE-1  –  specifi  c lympho-
cytes among infused TILs and relapse prevention (P   <   0.001), 
and thus, suggest the potential immunogenicity of this new 
HLA-A2 melanoma epitope. 
  Finally, to address the question of the diversity and tumor 
reactivity of the MELOE-1/A2  –  specifi  c repertoire, specifi  c 
lymphocytes were sorted by monomer-based immunomagnetic 
sorting (  23  ) from the fi  ve positive TIL populations.   Fig. 5 B   
(insets) illustrates the purity of sorted TILs assessed by specifi  c 
tetramer labeling. We also attempted to sort fi  ve negative TIL 
populations with monomer-coated beads, but no MELOE-1  –
  specifi  c cells were obtained (unpublished data). This last result 
formally documented the absence of such cells in those pop-
ulations, or at least showed that the frequencies of MELOE-1  –
  specifi  c T cells were too low to allow their purifi  cation by 
multimer sorting. The diversity of TCR V     usage of sorted 
populations was assessed with a panel of 25 anti-V     anti-
bodies representing the most frequently expressed V     chains 
within a normal repertoire. In M117, M170, and M278 sorted 
populations, eight or six diff  erent V     chains were signifi  -
cantly expressed (  >  1%) by MELOE-1/A2  –  specifi  c TILs, in-
dicating the presence of a rather polyclonal-specifi  c TCR 
repertoire (  Fig. 5 B  ). TCR diversity of M134 sorted TILs 
    meloe   is overexpressed in melanomas 
  To explain the absence of recognition of tumor cell lines 
other than melanomas, we examined the transcription level of 
  meloe   cDNA by quantitative PCR (qPCR;   Table II  ) in a panel 
of HLA-A2 tumor cell lines and melanocytes. The mean level 
of   meloe   expression in two HLA-A2 melanocytes was used as 
a reference to establish its relative expression in other cell 
lines. This analysis showed that   meloe   expression in melanomas 
was higher than in melanocytes, with values ranging from 3- 
to 34-fold higher, whereas this expression was signifi  cantly 
lower in other tumor cell lines, with values ranging from 5- to 
338-fold lower (  Fig. 4 A  ).   These results show that this antigen 
is overexpressed in melanomas, and thus, the protein encoded 
by the ORF 1,230  –  1,370 was called MELOE-1. Furthermore, 
    Figure 3.         Characterization of   meloe  -derived peptide recognized by 
the M170.48 T cell clone.   (A) Structure of   meloe   cDNA. Boxes illustrate 
ORFs   >  120 bp present along the   meloe   sequence, and black boxes corre-
spond to ORFs tested for recognition by the CTL clone. (B) M170.48 TNF 
responses to COS-7 cells (E/T ratio = 1:3) transfected with the indicated 
plasmids. The T cell clone was added 2 d after the transfection, and the CTL 
clone reactivity was assessed by a TNF release assay. (C) Nucleotide and 
amino acid sequences of the ORF 1,230  –  1,370 of   meloe   isolated from the 
M134 cDNA library. The two candidate peptides are bolded. (D) Cytotoxicity 
of the M170.48 CTL clone against peptide-pulsed T2 cells. Target cells were 
  51  Cr-labeled for 60 min and incubated for 30 min with a range of the indi-
cated peptides. The M170.48 T cell clone was added (E/T ratio = 10:1), and 
chromium release was then measured after a 4-h incubation period.     JEM VOL. 205, October 27, 2008 
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ORF, also recognized in the HLA-A*0201 context by a CTL 
clone deriving from the same TIL population, is under char-
acterization. This suggests that   meloe   could be an interesting 
source of tumor epitopes recognized by melanoma TILs. 
  The   meloe   antigen could be classifi  ed into the family of 
  “  melanocytic diff  erentiation antigens  ”   because of its expression 
in melanocytes and melanoma cell lines (  25  ). Nonetheless, it 
could be also classifi  ed into the family of aberrantly expressed 
antigens because of the particular location of   meloe   gene in the 
third intron of the HDAC-4 gene, according to the example 
of NA17-A antigen, located in an intron of the GnT-V gene 
(  6  ). Unlike classical diff  erentiation antigens such as Melan-A 
or tyrosinase (  18, 26, 27  ), we detected by qPCR a residual 
expression of the   meloe   gene in other cancer cell lines, even if 
this expression level was too low to induce their recognition 
by our specifi  c CTL clone, as recently shown for a mouse 
prostate tumor epitope derived from histone H4 (  28  ).   meloe   
also diff  ers from a classical diff  erentiation antigen by its over-
expression in melanomas, compared with normal melano-
cytes. Thus,   meloe   seems to be specifi  cally overexpressed in 
melanomas, and therefore, this new antigen presents both the 
properties of tissue specifi  city and overexpression in cancer. 
The reasons for its overexpression in melanomas could be be-
cause of the regulation of   meloe   promoter. As described for the 
MAGE-1 gene, a transient and general process of demethyl-
ation in tumors could be followed by a persistent inhibition of 
remethylation caused by the presence of melanoma-specifi  c 
transcription factors (  29  ). In this way,   meloe   overexpression in 
melanomas could be caused by the hypomethylation of its 
promoter in melanoma cell lines. In another way, melanoma-
specifi  c transcription factors, such as microphthalmia-associ-
ated transcription factor, which controls the expression of the 
three main melanocytic diff  erentiation antigens (  30, 31  ), could 
also control the overexpression of   meloe   in melanomas. 
was much lower, with a strong dominance of lymphocytes 
expressing the V    13.1 chain (  Fig. 5 B  ). This may be related 
to the low fraction of MELOE-1  –  specifi  c T cells present in 
this population before sorting (0.3% of CD8  +   TILs;   Fig. 5 A  ), 
which was probably poorly diverse. Finally, we could not 
determine the dominant V     chain expressed by TILs sorted 
from M180 with our panel of antibodies. Therefore, no domi-
nant V     usage could be observed within these three sorted TIL 
populations. Finally, to support the potential role of MELOE-1/
A2  –  specifi  c TIL transfer in relapse prevention, we studied the 
reactivity of sorted TIL populations on HLA-A*0201 mela-
noma cell lines that spontaneously express the MELOE-1 anti-
gen. All sorted T cell lines were lytic against melanoma cell 
lines (  Fig. 6 A   and not depicted) and produced IFN-     and 
TNF upon stimulation by these cells, with levels similar to the 
M170.48 CTL clone, and to a lower extent IL-2 (  Fig. 6 B   and 
not depicted).   
    DISCUSSION   
  The   meloe   gene is located on the third intron of the HDAC-4 
gene and translated in anti-sense orientation in comparison 
with the HDAC-4 gene (  24  ). There is a perfect colinearity 
between the   meloe   gene and its corresponding cDNA, show-
ing an absence of splicing of this gene. Furthermore, the 
structure of this 2.1-kb cDNA is rather unusual, with multi-
ple short ORFs instead of a unique long ORF. The protein 
encoded by the ORF  1230-1370   (MELOE-1) contains a peptide 
that was recognized by a CTL clone derived from melanoma-
specifi  c TILs, in the HLA-A*0201 context. This CTL clone 
recognized all of the HLA-A*0201 melanoma cell lines 
tested, and to a lower extent HLA-A*0201 melanocytes. On 
the other hand, this T cell clone failed to recognize any of the 
other tumor cell lines tested (  Fig. 1 C  ). Moreover, another 
epitope derived from the protein encoded by an alternative 
    Table II.        Sequences of primers used for qPCR and ORF subcloning 
Primers 5      –  3     sequences
qPCR
     RPLPO forward GTGATGTGCAGCTGATCAAGA
     RPLPO reverse GATGACCAGCCCAAAGGAGA
         2-microglobulin forward TTCACCCCCACTGAAAAAGAT
         2-microglobulin reverse GGCATCTTCAAACCTCCATGAT
       meloe   forward GTCCTCCCCAGCACCAGAGT
       meloe   reverse AGCCTGCCATCTGCAATCCT
ORF subcloning
     (285  –  404) forward aaa  GAATTC  gccaccATGAGTGAAAATGCAGGAGG
     (285  –  404) reverse aaa   CTCGAG   TCACTGGCACAGTGCAG
     (486  –  689) forward aaa  GAATTC  gccaccATGTCCGTAGGGAGACGC
     (486  –  689) reverse aaa   CTCGAG   TCACCCTAGAGCTGCCAAG
     (1,105  –  1,194) forward aaa  GAATTC  gccaccATGAAATTTGAATTAATTTGCAGAAC
     (1,105  –  1,194) reverse aaa   CTCGAG   TTAATTCCTAAGGCATTCATTC
     (1,230  –  1,370) forward aaa  GAATTC  gccaccATGAGTTGTGTAGGTTATCC
     (1,230  –  1,370) reverse aaa   CTCGAG   TCACAGGGATGCCGGCC
The italicized letters correspond to the enzyme restriction sites. The lowercased letters correspond to the Kozak sequence, which is described in the Materials and methods.2678 MELOE-1: AN ANTIGEN INVOLVED IN IMMUNOSURVEILLANCE   | Godet et al. 
cytes. This expression level is similar to that measured in healthy 
tissues by qPCR (  Fig. 4 C  ), suggesting that an immunization 
with this antigen should not induce deleterious reactions in 
healthy tissues, although we could expect the induction of some 
vitiligo because of the expression of   meloe   in melanocytes. 
  The second point concerns the immunogenicity of this 
new antigen and especially the immunogenicity of the HLA-
A*0201  –  restricted epitope. To answer this main question, 
we checked the presence of MELOE-1  –  specifi  c lymphocytes 
among TIL populations, which had been infused to stage III 
melanoma patients after lymph node excision, in an adjuvant 
setting. In retrospective studies of this adoptive transfer pro-
tocol, we already showed that the infusion of melanoma-spe-
cifi  c TILs had a signifi  cant impact on the relapse prevention 
of treated patients (  17  ). More recently, we found that pro-
longed relapse-free survival of TIL-treated patients correlated 
with the infusion of Melan-A  –  specifi  c lymphocytes (  14  ), al-
though a signifi  cant fraction of tumor-specifi  c TILs remains 
of unknown specifi  city in several TIL populations infused to 
relapse-free patients. We detected a signifi  cant fraction of 
MELOE-1  –  specifi  c lymphocytes, by tetramer labeling, in 
  Because of its expression widely shared by melanoma cell 
lines, and to the existence of an epitope recognized by a mela-
noma-reactive CTL in the HLA-A*0201 context, the MELOE-1 
antigen could be a promising target for future immunotherapy 
protocols of melanoma, provided that its usage remains safe in 
patients and that its immunogenicity could be documented. 
  Our data provide some arguments concerning the safety 
of immunization of patients with this antigen or of adoptive 
transfer with specifi  c CTLs. Indeed, the expression level of 
  meloe   in healthy tissues is always lower than in melanocytes, 
which are weakly recognized by the MELOE-1  –  specifi  c CTL 
clone to a lower extent than by Melan-A  –  specifi  c CTLs 
(  Figs. 1 D and 4 C  ). Furthermore, none of the other HLA-
A*0201 cancer cell lines was able to spontaneously induce any 
reactivity of the MELOE-1  –  specifi  c CTLs (  Fig. 1 C  ), even 
after a 48-h treatment with IFN-     (not depicted). MELOE-1  –
  specifi  c CTL clones could only be activated by such tumor 
cell lines when they were previously transfected by the   meloe   
cDNA or the cDNA coding for ORF  1230-1370   (  Fig. 4 B  ), 
showing that the expression level of   meloe   in other cancer cell 
lines was too low to induce the activation of specifi  c lympho-
    Figure 4.         Preferential expression of   meloe   cDNA in melanoma cell lines measured by qPCR, and impact of   meloe   expression on specifi  c CTL 
clone activation.   (A) Four melanoma, one breast cancer, two renal carcinoma, and one lung cancer cell lines were tested by qPCR for the expression of   meloe . 
RPLPO and     2-microglobulin gene expression were used as internal controls. The relative expression of   meloe   was calculated after normalization on the ef-
fi  ciency of the PCR reaction and the mean expression of these two housekeeping genes, reported to its normalized expression in melanocytes. (B) TNF secre-
tion by the M170.48 CTL clone in response to HLA-A2 tumor cell lines nontransfected (open bars) or transfected with   meloe   (hatched bars) or   meloe -1  (shaded 
bars) expression plasmids. Tumor cells were transiently transfected with 100 ng of each plasmid with a lipofectamine reagent kit. 10  4   CTLs were added to 3   ×   10  4  
target cells, and the CTL clone reactivity was assessed by a TNF release assay. (C)   meloe   relative expression measured by qPCR in 16 human healthy tissues.    JEM VOL. 205, October 27, 2008 
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  According to the example of Melan-A antigen, a diverse 
and tumor-reactive T cell repertoire is necessary to develop 
protocols of adoptive transfer of specifi  c T cells in melanoma 
patients, as well as for vaccination trials. We addressed this last 
issue by analyzing the diversity and reactivity of an MELOE-1  –
  specifi  c repertoire in the fi  ve TIL populations that con-
tained MELOE-1  –  specifi  c T cells. After the selection of 
MELOE-1  –  specifi  c T cells from TILs by immunomagnetic 
sorting with multimer-coated beads (  23  ), we showed that the 
MELOE-1  –  specifi  c repertoire was diverse in three out of 
fi  ve TIL populations and much more limited for the M134 
TIL population, which contained a low fraction of MELOE-1  –
  specifi  c T cells (  Fig. 5, A and B  ), which could explain this 
poorer diversity. We could not determined the dominant V     
chains expressed by M180 sorted TILs with our panel of an-
tibodies (  Fig. 5 B  ). The repertoire analysis of these TIL pop-
ulations did not reveal any recurrence of a particular V     usage, 
as previously described for the Melan-A  –  specifi  c repertoire (  23  ). 
5 out of 9 TIL populations infused to HLA-A2 patients who 
remained relapse free from 7 to 13 yr, whereas no MELOE-1  –
  specifi  c lymphocytes could be observed in 21 TIL populations 
infused to patients who relapsed. The statistical analysis of 
these results performed by a       2   test documents a correlation 
between the prevention of the relapse of TIL-treated HLA-
A2 patients and the presence of MELOE-1  –  specifi  c CTLs 
among those TILs (P   <   0.001). This main result provides a 
strong argument in favor of the implication of MELOE-1 
antigen in the immunosurveillance of patients treated by 
adoptive transfer of TILs. This role in immunosurveillance 
has not been formally elucidated for the majority of mela-
noma antigens identifi  ed, except for Melan-A/MART-1, which 
seems clearly involved in clinical responses of melanoma pa-
tients treated by immunotherapy (  10  –  12, 14, 15  ). 
    Figure 5.         Detection of M  ELOE  -1/A2  –  specifi  c CTLs in TILs infused 
to relapse-free melanoma patients and analysis of their repertoire 
diversity.   (A) HLA-A2 TIL populations labeled with the A2/M  ELOE  -1  36-44   tetra-
mer. (top) TILs infused to relapse-free patients. (bottom) TILs infused to 
patients who relapsed. TILs were coincubated with M  ELOE  -1 tetramer and anti-
CD8 mAb. Values indicate the percentage of tetramer-positive cells among 
CD8  +   TILs. (B) Repertoire diversity of multimer-sorted populations was eval-
uated by labeling with 25 anti-V     mAbs. Insets illustrate the purity of each 
sorted TIL population, assessed by M  ELOE  -1  –  specifi  c tetramer labeling.    
    Figure 6.              Reactivity of M  ELOE  -1/A2  –  specifi  c TILs against HLA-A2 
tumor cell lines.   (A) Lysis of the M170 melanoma cell line (closed circles) 
and of the 1355 lung carcinoma cell line (open circles) by the M170.48 CTL 
clone  and  M ELOE -1 – specifi  c TIL populations.   51  Cr-labeled tumor cells were 
co-cultured with T cells at various E/T ratios. Chromium release in the su-
pernatants was measured after a 4-h incubation period. (B) Cytokine pro-
duction by the M170.48 CTL clone and M  ELOE  -1  –  specifi  c TIL populations in 
response to M170 melanoma cells. Effector and target cells were incubated 
at a 1:2 ratio in the presence of Brefeldin A and stained with anti-TNF anti-
body (open bars), anti  –   IFN-     antibody (hatched bars), or anti  –  IL-2 anti-
body (closed bars), and 10  4   T cells were analyzed by fl  ow cytometry.     2680 MELOE-1: AN ANTIGEN INVOLVED IN IMMUNOSURVEILLANCE   | Godet et al. 
France) for B1.23.2 antibody. Intracellular staining of cytokines was per-
formed as previously described on stimulated T cells (  36  ). 
  cDNA library and ORF constructs.     The M134 cDNA library has been 
inserted in pcDNA3.1, as described previously (  20  ), and recombinant plas-
mids were electroporated into   Escherichia coli   XL1 (Stratagene). For screen-
ing, 800 pools of 100 ampicillin-resistant bacteria were constituted. Plasmid 
DNA was extracted from each pool with the QIAprep Spin Miniprep kit 
(QIAGEN). The positive plasmid was sequenced by the DNA Sequencing 
Facility of the Institut F  é  d  é  ratif de Recherche 26. The various ORFs from 
the   meloe   sequence were generated by PCR (primers are available in   Table II  ). 
Oligonucleotides were designed with EcoRI and XhoI adaptators for sub-
cloning in pcDNA3, and with a Kozak sequence (gccaccATG) for the upper 
primer and a stop codon for the lower primer. 
  Synthetic peptides.     Peptides were purchased from Eurogentec. Purity 
(  >  70 or   >  90% for tetramer production) was controlled by reversed-phase 
HPLC. Peptides were lyophilized, dissolved in DMSO at 10 mg/ml, and 
stored at     20  °  C. 
  Real-time PCR.     Total RNA was extracted from tumor cell lines, me-
lanocytes, and B-EBV cell lines by TRI  zol   reagent (Invitrogen). RNA 
from healthy tissues were purchased from Clontech Laboratories, Inc. The 
quality of RNA samples was controlled using a bioanalyzer (Agilent 2100 
Bioanalyzer; Agilent Technologies), and all of the samples exhibited an 
RNA integrity number   >  7. Retrotranscription was performed using 1   μ  g 
of total RNA, random hexamers, and SuperScript II reverse transcriptase 
(Invitrogen). Relative quantifi  cation of   meloe  , RPLPO, and     2-micro-
globulin expression was performed using Brilliant SYBR Green QPCR 
in an Mx4000 machine (Stratagene). 10 ng of cDNA from samples was 
added to SYBR Green Master Mix in an Mx4000 machine with forward 
and reverse primers (  Table II  ) at 200 nM in a fi  nal volume of 25   μ  l. 
Thermal cycling was one step at 95  °  C for 10 min, followed by 40 cycles 
at 95  °  C for 30 s, 63  °  C for 1 min, and 72  °  C for 1 min. The effi   ciency of 
PCR reaction was determined with a series of 10-fold  –  diluted cDNA 
from patient M170, performed in parallel to plot the standard curves for 
  meloe  , RPLPO, and     2-microglobulin. Duplicate dilution series were in-
cluded as standards in each run. Mean threshold cycle (  CT  ) values from 
duplicate PCR reactions were normalized to mean   CT   values for two 
housekeeping genes (    2-microglobulin and RPLPO) from the same cDNA 
preparations. The relative expression ratio of a target gene was calculated 
based on the PCR effi   ciency (  E  ) and the   CT   deviation between a given 
cell line (  x  ) and a reference cell line (  calibrator  ), expressed in comparison with 
the mean of the housekeeping genes (  37  ): ratio = (  E  target)    Δ       CT      target(calibrator    x)  /
mean((  E  housekeeping)    Δ       CT      housekeeping(calibrator    x)  ). 
  Tetramer and V     labeling.     HLA-A*0201/  MELOE-1   and HLA-A*0201/
Melan-A     3-mutated monomers were generated by the recombinant pro-
tein facility (INSERM U892), as previously described (  38  ). TIL populations 
and the M170.48 T cell clone were coincubated for 1 h at 4  °  C in the dark 
with 10   μ  g/ml of   MELOE-1   tetramer and 5   μ  g/ml CD8 mAb, and 10  4   events 
were analyzed on a FACSCalibur (BD Biosciences). A panel of 25 anti-V     
mAbs (V    1, -2, -3, -4, -5.1, -5.2, -5.3, -6, -7, -7.2, -8, -9, -11, -12, -13.1, 
-13.2, -13.6, -14, -16, -17, -18, -20, -21.3, -22, and -23) was used to ana-
lyze the diversity of sorted TIL populations (Beckman Coulter). 
  Immunomagnetic cell sorting and expansion of T cell  –  sorted pop-
ulations.     20   μ  g/ml of HLA-A*0201/  MELOE-  1 monomers were incu-
bated for 1 h at room temperature with 6.7   ×   10  6   streptavidin-coated beads 
(Dynabeads M-280 streptavidin; Invitrogen) and washed in PBS/0.1% BSA. 
5   ×   10  6   TILs were rotated for 4 h at 4  °  C with monomer-coated beads 
(  23, 38  ). After 10 washes, bead-coated cells were expanded using a polyclonal 
T cell stimulation protocol (  33  ). 
  We acknowledge Professor F. Lang and Dr. M. Bonneville for carefully reading the 
manuscript. We thank the recombinant platform facility of the Institut F  é  d  é  ratif 
These fi  ve MELOE-1  –  specifi  c TIL populations were as reac-
tive as the M170.48-specifi  c T cell clone against HLA-A2 mela-
noma cell lines, as shown by lysis (  Fig. 6 A  ) and IFN-     and 
TNF-     production in response to melanoma cells, and, to a 
lower extent, IL-2 production. Furthermore, we recently dem-
onstrated that MELOE-1  –  specifi  c T cells could be also se-
lected and amplifi  ed from the PBMCs of melanoma patients 
(unpublished data), which remain the most convenient source 
of tumor-specifi  c T cells usable for all HLA-A2 patients en-
rolled in adoptive transfer protocols. 
  In conclusion, this new melanoma antigen,   meloe  , appears 
to be a very relevant target for immunotherapy protocols. Its 
overexpression by all melanoma cell lines tested, the particu-
lar structure of the transcript with multiple ORFs, its poten-
tial as a source of class I and II epitopes, the characterization 
of an epitope derived from one of these ORFs and recog-
nized in the frequently expressed HLA-A2 context, and, fi  -
nally, its implication in the immunosurveillance of TIL-treated 
HLA-A2 melanoma patients are convincing arguments to use 
this antigen in vaccination trials or to target it by the adoptive 
transfer of specifi  c T cells. 
  MATERIALS AND METHODS 
  Cell lines and TIL cultures.     20 T cell populations were expanded from 
cryopreserved samples of TILs (derived from tumor-invaded lymph nodes) in-
fused to melanoma patients included in a phase I/II protocol between the years 
1994 and 1998. This clinical trial aimed at examining the survival of stage III 
melanoma patients randomly treated by IL-2 alone, or TIL plus IL-2, in an ad-
juvant setting (  16  ). 10 additional HLA-A2 stage III melanoma patients, treated 
with TIL and IL-2 in an adjuvant setting, were also analyzed in the present 
study. They have been enrolled between December 2001 and June 2006 ei-
ther in a clinical open study or in a multicentric trial. All of these clinical trials 
were approved by the local ethics committee Comit  é   de Protection des Per-
sonnes Ouest IV  –  Nantes and the Agence fran  ç  aise de s  é  curit  é   sanitaire des 
produits de sant  é  . TIL samples were expanded according to a previously de-
scribed procedure (  32, 33  ). TILs containing tumor-specifi  c T cells were cloned 
by limiting dilution (  34  ), and tumor-specifi  c T cell clones were amplifi  ed as 
previously described (  33  ). Melanoma cells lines and colorectal carcinoma cell 
line C4-A were established, respectively, in the Unit of Cellular Therapy and 
in our laboratory. Mouse fi  brosarcoma WEHI 164 clone 13 and COS-7 cells 
were obtained from T. Boon (Ludwig Institute for Cancer Research, Brussels, 
Belgium). Ovary carcinoma cell lines (OVCAR-3 and O114) and renal carci-
noma cell line A498 were gifts from C. Sa  ï   (Institut National de la Sant  é   et de 
la Recherche M  é  dicale [INSERM] U892, Nantes, France). Colorectal carci-
noma cell lines (CaCo-2, Sw480, Sw707, and LS174T), renal carcinoma 
cell line HTC116, and breast carcinoma cell line 734-B were gifts from M. 
Gr  é  goire (INSERM U601, Nantes, France), S. Chouaib (INSERM U487, 
Villejuif, France), and D. J  ä  ger (Klinik und Poliklinik f  ü  r Onkologie, Z  ü  rich, 
Germany). Breast cancer cell line MCF-7 was obtained from the American 
Type Culture Collection. Normal melanocytes (98M09 and 01M08) were 
gifts from M. Regnier (L  ’  Or  é  al Laboratory, Paris, France). EBV-B cell lines 
were gifts from H. Vi  é   (INSERM U601, Nantes, France). 
  Functional analysis of T cells.     Cytotoxic activity of T cells was measured 
in a standard 4-h assay against   51  Cr-labeled cells (peptide-loaded T2 cells or 
tumor cell lines) (  23  ). Measurement of TNF produced by T cells in response 
to tumor cells or transfected COS-7 cells (  19  ) was performed as previously 
described, using WEHI 164 clone 13 cells (  35  ). mAb against HLA class I 
(clone W6.32), HLA-B/C (clone B1.23.2), and HLA-A2 (clone BB7.2), 
added to cultures in some experiments, were produced in our laboratory 
from hybridomas obtained from the American Type Culture Collection for 
W6.32 and BB7.2 antibodies and from F. Lemonier (Pasteur Institute, Paris, JEM VOL. 205, October 27, 2008 
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